Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

William C. Knowler, Elizabeth Barrett-Connor, Sarah E. Fowler, Richard F. Hamman, John M. Lachin, Elizabeth A. Walker, David M. Nathan

Research output: Contribution to journalArticle

12223 Citations (Scopus)

Abstract

Background: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors - elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle - are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. Methods: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups. Results: The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. Conclusions: Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.

Original languageEnglish (US)
Pages (from-to)393-403
Number of pages11
JournalNew England Journal of Medicine
Volume346
Issue number6
DOIs
StatePublished - Feb 7 2002
Externally publishedYes

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Life Style
Incidence
Placebos
Glucose
Fasting
Confidence Intervals
Sedentary Lifestyle
Minority Groups
Weight Loss
Body Mass Index
Exercise
Weights and Measures

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. / Knowler, William C.; Barrett-Connor, Elizabeth; Fowler, Sarah E.; Hamman, Richard F.; Lachin, John M.; Walker, Elizabeth A.; Nathan, David M.

In: New England Journal of Medicine, Vol. 346, No. 6, 07.02.2002, p. 393-403.

Research output: Contribution to journalArticle

Knowler, WC, Barrett-Connor, E, Fowler, SE, Hamman, RF, Lachin, JM, Walker, EA & Nathan, DM 2002, 'Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin', New England Journal of Medicine, vol. 346, no. 6, pp. 393-403. https://doi.org/10.1056/NEJMoa012512
Knowler, William C. ; Barrett-Connor, Elizabeth ; Fowler, Sarah E. ; Hamman, Richard F. ; Lachin, John M. ; Walker, Elizabeth A. ; Nathan, David M. / Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. In: New England Journal of Medicine. 2002 ; Vol. 346, No. 6. pp. 393-403.
@article{84b876dd72ab46949583ae106de83225,
title = "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin",
abstract = "Background: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors - elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle - are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. Methods: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups. Results: The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. Conclusions: Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.",
author = "Knowler, {William C.} and Elizabeth Barrett-Connor and Fowler, {Sarah E.} and Hamman, {Richard F.} and Lachin, {John M.} and Walker, {Elizabeth A.} and Nathan, {David M.}",
year = "2002",
month = "2",
day = "7",
doi = "10.1056/NEJMoa012512",
language = "English (US)",
volume = "346",
pages = "393--403",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "6",

}

TY - JOUR

T1 - Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

AU - Knowler, William C.

AU - Barrett-Connor, Elizabeth

AU - Fowler, Sarah E.

AU - Hamman, Richard F.

AU - Lachin, John M.

AU - Walker, Elizabeth A.

AU - Nathan, David M.

PY - 2002/2/7

Y1 - 2002/2/7

N2 - Background: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors - elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle - are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. Methods: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups. Results: The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. Conclusions: Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.

AB - Background: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors - elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle - are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. Methods: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups. Results: The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. Conclusions: Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.

UR - http://www.scopus.com/inward/record.url?scp=0037034257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037034257&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa012512

DO - 10.1056/NEJMoa012512

M3 - Article

C2 - 11832527

AN - SCOPUS:0037034257

VL - 346

SP - 393

EP - 403

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 6

ER -